Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Small Cell Lung Carcinoma × EC regimen × Clear all

Phase

Phase 2 3 Phase 1/2 2 Phase 3 1 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1 Carcinoma, Neuroendocrine 1 Breast Neoplasms 1

Interventions

Drug Therapy 2 sintilimab 1 dinutuximab 1 atezolizumab 1 Topotecan 1 SR 48692 1 Rabeprazole 1 Irinotecan 1 Etoposide 1 Electroporation 1 EC regimen 1 E-3810 1 Cryosurgery 1 Carboplatin 1 Bevacizumab 1 2,2',4,4',5-pentachlorodiphenyl ether 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04254471 2020-02-05

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Haihe Biopharma Co., Ltd.

Phase 2/3 Unknown

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡